Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Roche (RHHBY - Analyst Report) recently announced that its Board of Directors will propose to elect Christoph Franz as the new Chairman at the Annual Shareholder Meeting scheduled for Mar 2014.

Franz is nominated to succeed the current Chairman, Franz B. Humer, who would not be standing for re-election. Humer has been serving Roche in numerous positions since 1995.

Franz is currently the Chief Executive Officer (CEO) of the Germany-based Lufthansa Group. However, he will not renew his contract as the company’s CEO beyond May 2014. We remind investors that Franz has also been on Roche’s Board since 2011.

We note that Roche Holding is a leading healthcare company which discovers, develops and provides innovative therapeutic drugs for diverse medical needs in over 150 countries.

Apart from providing therapeutic products and services for diverse medical needs, Roche also focuses on innovative diagnostic solutions for the early detection and treatment of diseases.

The company generated revenues of CHF 45.5 billion in 2012. The core area of focus for Roche continues to be oncology, which accounted for 61% of total pharmaceutical sales in 2012.

We were impressed by the company’s solid performance in the first half of 2013.  The outlook for 2013 is bright as well.

Roche continues to expect sales in 2013 to increase in line with 2012 growth rates. Roche expects core earnings per share to grow at a higher rate than sales in 2013. Moreover, Roche expects to further increase its dividend in 2013.

However, increasing competition from biosimilars will pose as a major challenge for the new Chairman.

Roche currently carries a Zacks Rank #1 (Strong Buy). Other stocks that look attractive include Bayer (BAYRY - Analyst Report), Novo Nordisk (NVO - Analyst Report) and Jazz Pharmaceuticals (JAZZ - Analyst Report). All three carry a Zacks Rank #2 (Buy). 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%